Da An Gene Co Ltd of Sun Yat-Sen University
Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coro… Read more
Da An Gene Co Ltd of Sun Yat-Sen University (002030) - Net Assets
Latest net assets as of September 2025: CN¥7.99 Billion CNY
Based on the latest financial reports, Da An Gene Co Ltd of Sun Yat-Sen University (002030) has net assets worth CN¥7.99 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.09 Billion) and total liabilities (CN¥1.10 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.99 Billion |
| % of Total Assets | 87.91% |
| Annual Growth Rate | 24.73% |
| 5-Year Change | 80.37% |
| 10-Year Change | 319.81% |
| Growth Volatility | 46.57 |
Da An Gene Co Ltd of Sun Yat-Sen University - Net Assets Trend (2001–2024)
This chart illustrates how Da An Gene Co Ltd of Sun Yat-Sen University's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Da An Gene Co Ltd of Sun Yat-Sen University (2001–2024)
The table below shows the annual net assets of Da An Gene Co Ltd of Sun Yat-Sen University from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.14 Billion | -11.07% |
| 2023-12-31 | CN¥9.16 Billion | -21.17% |
| 2022-12-31 | CN¥11.62 Billion | +51.64% |
| 2021-12-31 | CN¥7.66 Billion | +69.67% |
| 2020-12-31 | CN¥4.51 Billion | +116.27% |
| 2019-12-31 | CN¥2.09 Billion | -5.14% |
| 2018-12-31 | CN¥2.20 Billion | -16.70% |
| 2017-12-31 | CN¥2.64 Billion | +3.47% |
| 2016-12-31 | CN¥2.55 Billion | +31.63% |
| 2015-12-31 | CN¥1.94 Billion | +112.07% |
| 2014-12-31 | CN¥914.64 Million | +20.65% |
| 2013-12-31 | CN¥758.10 Million | +21.06% |
| 2012-12-31 | CN¥626.21 Million | +13.01% |
| 2011-12-31 | CN¥554.12 Million | +14.88% |
| 2010-12-31 | CN¥482.34 Million | +12.54% |
| 2009-12-31 | CN¥428.60 Million | +11.24% |
| 2008-12-31 | CN¥385.31 Million | +24.63% |
| 2007-12-31 | CN¥309.15 Million | +10.14% |
| 2006-12-31 | CN¥280.69 Million | +4.08% |
| 2005-12-31 | CN¥269.70 Million | +5.06% |
| 2004-12-31 | CN¥256.72 Million | +178.80% |
| 2003-12-31 | CN¥92.08 Million | +33.40% |
| 2002-12-31 | CN¥69.03 Million | +36.68% |
| 2001-12-31 | CN¥50.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Da An Gene Co Ltd of Sun Yat-Sen University's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 40972.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.61 Billion | 58.52% |
| Common Stock | CN¥1.40 Billion | 17.81% |
| Other Comprehensive Income | CN¥1.76 Billion | 22.38% |
| Other Components | CN¥101.94 Million | 1.29% |
| Total Equity | CN¥7.88 Billion | 100.00% |
Da An Gene Co Ltd of Sun Yat-Sen University Competitors by Market Cap
The table below lists competitors of Da An Gene Co Ltd of Sun Yat-Sen University ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NCAB Group
ST:NCAB
|
$784.83 Million |
|
Shanghai Tofflon Science Tech
SHE:300171
|
$784.88 Million |
|
Genco Shipping & Trading Ltd
NYSE:GNK
|
$785.23 Million |
|
Shenzhen Sunrise New Energy Co Ltd
SHE:002256
|
$785.39 Million |
|
ASA Gold and Precious Metals Ltd
NYSE:ASA
|
$784.17 Million |
|
BioLife Solutions Inc
NASDAQ:BLFS
|
$784.06 Million |
|
Shanghai SMI Holding Co Ltd
SHG:600649
|
$784.03 Million |
|
Noah Holdings Ltd
NYSE:NOAH
|
$783.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Da An Gene Co Ltd of Sun Yat-Sen University's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,880,234,790 to 7,879,949,193, a change of -1,000,285,597 (-11.3%).
- Net loss of 925,169,858 reduced equity.
- Dividend payments of 27,879,255 reduced retained earnings.
- Other comprehensive income decreased equity by 54,064,041.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-925.17 Million | -11.74% |
| Dividends Paid | CN¥27.88 Million | -0.35% |
| Other Comprehensive Income | CN¥-54.06 Million | -0.69% |
| Other Changes | CN¥6.83 Million | +0.09% |
| Total Change | CN¥- | -11.26% |
Book Value vs Market Value Analysis
This analysis compares Da An Gene Co Ltd of Sun Yat-Sen University's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 174.45x to 1.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CN¥0.04 | CN¥6.16 | x |
| 2002-12-31 | CN¥0.05 | CN¥6.16 | x |
| 2003-12-31 | CN¥0.07 | CN¥6.16 | x |
| 2004-12-31 | CN¥0.22 | CN¥6.16 | x |
| 2005-12-31 | CN¥0.23 | CN¥6.16 | x |
| 2006-12-31 | CN¥0.24 | CN¥6.16 | x |
| 2007-12-31 | CN¥0.25 | CN¥6.16 | x |
| 2008-12-31 | CN¥0.29 | CN¥6.16 | x |
| 2009-12-31 | CN¥0.26 | CN¥6.16 | x |
| 2010-12-31 | CN¥0.29 | CN¥6.16 | x |
| 2011-12-31 | CN¥0.34 | CN¥6.16 | x |
| 2012-12-31 | CN¥0.41 | CN¥6.16 | x |
| 2013-12-31 | CN¥0.50 | CN¥6.16 | x |
| 2014-12-31 | CN¥0.60 | CN¥6.16 | x |
| 2015-12-31 | CN¥0.95 | CN¥6.16 | x |
| 2016-12-31 | CN¥1.17 | CN¥6.16 | x |
| 2017-12-31 | CN¥1.21 | CN¥6.16 | x |
| 2018-12-31 | CN¥1.29 | CN¥6.16 | x |
| 2019-12-31 | CN¥1.31 | CN¥6.16 | x |
| 2020-12-31 | CN¥3.04 | CN¥6.16 | x |
| 2021-12-31 | CN¥5.24 | CN¥6.16 | x |
| 2022-12-31 | CN¥8.05 | CN¥6.16 | x |
| 2023-12-31 | CN¥6.33 | CN¥6.16 | x |
| 2024-12-31 | CN¥5.62 | CN¥6.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Da An Gene Co Ltd of Sun Yat-Sen University utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -108.46%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.22x
- Recent ROE (-11.74%) is below the historical average (16.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 28.43% | 19.54% | 0.72x | 2.01x | CN¥9.13 Million |
| 2002 | 27.25% | 18.17% | 0.78x | 1.92x | CN¥11.75 Million |
| 2003 | 25.23% | 17.43% | 0.75x | 1.93x | CN¥13.94 Million |
| 2004 | 9.84% | 16.17% | 0.50x | 1.22x | CN¥-416.85K |
| 2005 | 9.81% | 16.19% | 0.55x | 1.11x | CN¥-514.16K |
| 2006 | 10.41% | 16.66% | 0.53x | 1.18x | CN¥1.13 Million |
| 2007 | 11.49% | 16.90% | 0.49x | 1.40x | CN¥4.53 Million |
| 2008 | 10.66% | 14.61% | 0.45x | 1.62x | CN¥2.15 Million |
| 2009 | 12.80% | 14.82% | 0.55x | 1.58x | CN¥10.36 Million |
| 2010 | 13.41% | 15.26% | 0.55x | 1.60x | CN¥14.35 Million |
| 2011 | 13.85% | 14.86% | 0.58x | 1.60x | CN¥18.92 Million |
| 2012 | 15.73% | 15.47% | 0.64x | 1.59x | CN¥32.84 Million |
| 2013 | 20.50% | 16.83% | 0.74x | 1.65x | CN¥73.62 Million |
| 2014 | 17.97% | 14.09% | 0.68x | 1.87x | CN¥67.90 Million |
| 2015 | 7.63% | 6.87% | 0.48x | 2.29x | CN¥-31.47 Million |
| 2016 | 6.63% | 6.62% | 0.39x | 2.57x | CN¥-54.26 Million |
| 2017 | 5.15% | 5.60% | 0.33x | 2.76x | CN¥-81.56 Million |
| 2018 | 5.59% | 6.87% | 0.40x | 2.02x | CN¥-80.00 Million |
| 2019 | 5.01% | 8.39% | 0.31x | 1.93x | CN¥-91.97 Million |
| 2020 | 57.37% | 45.85% | 0.80x | 1.57x | CN¥2.02 Billion |
| 2021 | 49.22% | 47.21% | 0.74x | 1.41x | CN¥2.88 Billion |
| 2022 | 47.89% | 44.93% | 0.82x | 1.31x | CN¥4.28 Billion |
| 2023 | 1.18% | 8.86% | 0.11x | 1.24x | CN¥-783.36 Million |
| 2024 | -11.74% | -108.46% | 0.09x | 1.22x | CN¥-1.71 Billion |
Industry Comparison
This section compares Da An Gene Co Ltd of Sun Yat-Sen University's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $927,289,280
- Average return on equity (ROE) among peers: 15.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | CN¥7.99 Billion | 28.43% | 0.14x | $784.18 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |